Full versus prophylactic heparinization for the treatment of severe forms of SARS-Covid-19: clinical, randomized, open and controlled study - HeSAcovid trial

Faculdade de Medicina de Ribeirão Preto0 个研究点开始时间: 2020年5月6日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Age above or equal to 18 years; SARS-covid-19 infection confirmed through RT-PCR; Severe forms confirmed by the presence of ARDS according to the Berlin classification ( bilateral infiltrate on chest X-ray, arterial hypoxemia with a PaO2 / FIO2 ratio <300, absence of structural heart disease or evidence of insufficiency acute cardiac arrest; Presence of severe clinical presentation with respiratory failure requiring orotracheal intubation or mechanical ventilation or maintenance of RF> 24 ipm and saturation <90% after the administration of supplemental oxygen through a nasal catheter at 4 liters / min; Dosage of D-dimer greater than and equal to 0.5 pg / ml; Presence of prothrombin time (TP / INR) <1.5 and APTT (activated partial thromboplastin time (APTT) <1.5; Platelet count greater than 100,000 / mm3

•Age over 85 years; creatinine clearance <10 ml / min; severe circulatory shock with a dose of norepinephrine greater than 1.0 pg / Kg / min; Chronic renal patients on hemodialysis; chronic Child B and C liver disease; advanced diseases (active neoplasia, heart failure functional class III and IV, COPD in chronic use of oxygen with more than 2 exacerbations in the last year, advanced dementia, bedridden patient with significant sequelae of stroke or traumatic brain injury; cardiorespiratory arrest; pregnant women; recent major surgery in the last 3 weeks; recent stroke in the last 3 months; presence of active bleeding; presence of blood dyscrasia such as: hemophilia, Von Willebrand factor deficiency, etc.; participation in another clinical investigation with associated intervention; formal indication for oral anticoagulation for other reasons such as: pulmonary embolism, acute coronary syndrome, etc.

发起方

Faculdade de Medicina de Ribeirão Preto